These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 27521286

  • 1. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
    Jeong Y, Lee JL.
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
    [Abstract] [Full Text] [Related]

  • 2. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
    Yashi M, Nishihara D, Mizuno T, Yuki H, Masuda A, Kambara T, Betsunoh H, Abe H, Fukabori Y, Muraishi O, Kamai T.
    Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
    [Abstract] [Full Text] [Related]

  • 3. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G.
    Cancer; 2014 Dec 15; 120(24):3923-31. PubMed ID: 25111199
    [Abstract] [Full Text] [Related]

  • 4. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Barroso-Sousa R, da Fonseca LG, Souza KT, Chaves AC, Kann AG, de Castro G, Dzik C.
    Med Oncol; 2015 Jan 15; 32(1):443. PubMed ID: 25519824
    [Abstract] [Full Text] [Related]

  • 5. Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.
    Dabkara D, Ganguly S, Biswas B, Ghosh J.
    Indian J Cancer; 2018 Jan 15; 55(1):94-97. PubMed ID: 30147102
    [Abstract] [Full Text] [Related]

  • 6. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
    Calvani N, Morelli F, Naglieri E, Gnoni A, Chiuri VE, Orlando L, Fedele P, Cinieri S.
    Med Oncol; 2019 Aug 09; 36(9):80. PubMed ID: 31399784
    [Abstract] [Full Text] [Related]

  • 7. [Metronomic chemotherapy with oral cyclophosphamide : An individual option for the metastatic castration-resistant prostate cancer patient?].
    Knipper S, Mandel P, V Amsberg G, Strölin P, Graefen M, Steuber T.
    Urologe A; 2019 Apr 09; 58(4):410-417. PubMed ID: 29808369
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
    Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y.
    Jpn J Clin Oncol; 2017 Mar 01; 47(3):247-251. PubMed ID: 28042138
    [Abstract] [Full Text] [Related]

  • 10. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
    Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J.
    Oncotarget; 2015 Jul 20; 6(20):18192-205. PubMed ID: 26078335
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
    Jpn J Clin Oncol; 2015 Aug 20; 45(8):774-9. PubMed ID: 25981621
    [Abstract] [Full Text] [Related]

  • 13. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G.
    Clin Cancer Res; 2009 Aug 01; 15(15):4954-62. PubMed ID: 19622584
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y.
    Int J Urol; 2019 Aug 01; 26(8):797-803. PubMed ID: 31055879
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
    Barata PC, Cooney M, Mendiratta P, Gupta R, Dreicer R, Garcia JA.
    Invest New Drugs; 2019 Apr 01; 37(2):331-337. PubMed ID: 30402678
    [Abstract] [Full Text] [Related]

  • 17. Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
    Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N.
    Urol Oncol; 2016 Jun 01; 34(6):254.e7-254.e13. PubMed ID: 26850781
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study.
    Zhang L, Zhou L, Shi Y, An X.
    Asian J Surg; 2024 Aug 01; 47(8):3577-3578. PubMed ID: 38644125
    [No Abstract] [Full Text] [Related]

  • 20. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.
    Eur Urol; 2017 Apr 01; 71(4):656-664. PubMed ID: 27402060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.